Navigation Links
For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain
Date:12/7/2009

WALTHAM, Mass., Dec. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.

The new Special European Physician & Payer Forum report entitled Metastatic Colorectal Cancer in Europe: Changing Dynamics in Light of Increasing Segmentation and New Therapeutic Options finds that more than half of surveyed oncologists in Germany, France and Spain indicate that the existence of a validated biomarker for Erbitux has decreased their prescribing of Avastin in a subpopulation of patients with metastatic colorectal cancer. Sales of Erbitux in these countries will be driven by its use to treat patients with wild-type KRAS (Kirsten rat sarcoma 2 viral oncogene) metastatic colorectal cancer. However, the existence of a validated biomarker for Erbitux has not had a significant impact on the prescribing of Avastin in Italy, which is likely due to the currently low levels of KRAS testing in this country.

"More than half of oncologists in France and Italy say they use Avastin-containing regimens as first-line treatment in patients known to have wild-type KRAS metastatic colorectal cancer, despite a valid biomarker proving the efficacy of Erbitux in this population," said Decision Resources Analyst Marcus Hoyle, B.Sc. "However, in Spain, the majority of oncologists say they use Erbitux-containing regimens in this setting, which is most likely due to the high levels of KRAS testing in Spain as compared to other countries."

The report finds that reimbursement of KRAS testing varies between the European countries surveyed. In France and Spain, KRAS testing is reimbursed but in Germany KRAS testing is not covered by all health insurance systems. As a result, the proportion of patients tested for KRAS status in Germany is substantially lower than the proportion tested in France and Spain. The proportion of patients tested for KRAS status in the United Kingdom, which is currently low, will increase significantly over the next 12 months.

Metastatic Colorectal Cancer in Europe: Changing Dynamics in Light of Increasing Segmentation and New Therapeutic Options is based on surveys with 224 oncologists and interviews with 20 hospital-based payers in Germany, France, Italy, Spain and the United Kingdom. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


For more information, contact:

Decision Resources                        Decision Resources, Inc.
Christopher Comfort                       Elizabeth Marshall
781-296-2597                              781-296-2563
ccomfort@dresources.com                   emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... September 26, 2017 , ... “How to Live in the Millennium”: a gripping take on ... are no longer a part of everyday life and do not affect daily choices. ... responsibility for the thoughts, words, and actions that are chosen. “How to Live in ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Sound of My Song”: an intriguing ... of published author, Karmen Worden, a retired teacher with a passion for music and ... an intriguing and inspiring story on loss, living with depression, and finding love through ...
(Date:9/26/2017)... ... ... Guide”: is the life story of the author and the exciting times this adventurer has ... an adventure tour guide and the subject of the book. , “Quickly slapping a ... faces. I played it off as a part of the adventure tour, an “added bonus” ...
(Date:9/26/2017)... ... ... Time out for Daddy is a moving story of a family's unconditional love for ... Out for Daddy” is the creation of published author Debra Titus, who has lived ... inspired her to write this book. , Published by Christian Faith Publishing, Debra Titus’s ...
(Date:9/25/2017)... ... September 25, 2017 , ... Sensogram Technologies ... programmable fall detection smart watch. VitalBand provides elite level fall detection, automatically ... want so help arrives quickly. Plus, it’s a fully functioning smart watch ...
Breaking Medicine News(10 mins):